HIV Citation List: February 3 - February 16, 2012

Pubmed citations

1. Identification of HIV Inhibitors Guided by Free Energy Perturbation Calculations. Acevedo, O., Z. Ambrose, P.T. Flaherty, H. Aamer, P. Jain, and S.V. Sambasivarao, Current Pharmaceutical Design, 2012. [Epub ahead of print]; PMID[22316150].
[Pubmed]. HIV_0203-021612.

2. Lower than Expected Maraviroc Concentrations in Cerebrospinal Fluid Exceed the Wild-type CCR5-tropic HIV-1 50% Inhibitory Concentration. Croteau, D., B.M. Best, S. Letendre, S.S. Rossi, R.J. Ellis, D.B. Clifford, A.C. Collier, B.B. Gelman, J.C. McArthur, J.A. McCutchan, S. Morgello, and I. Grant, AIDS, 2012. [Epub ahead of print]; PMID[22313954].
[Pubmed]. HIV_0203-021612.

3. Polyanionic N-donor Ligands as Chelating Agents in Transition Metal Complexes: Synthesis, Structural Characterization and Antiviral Properties Against HIV. Garcia-Gallego, S., J.S. Rodriguez, J.L. Jimenez, M. Cangiotti, M.F. Ottaviani, M.A. Munoz-Fernandez, R. Gomez, and F.J. de la Mata, Dalton Transactions, 2012. [Epub ahead of print]; PMID[22314266].
[Pubmed]. HIV_0203-021612.

4. Pre-clinical Evaluation of the HIV-1 Fusion Inhibitor L'644 as a Potential Candidate Microbicide. Harman, S., C. Herrera, N. Armanasco, J. Nuttall, and R.J. Shattock, Antimicrobial Agents and Chemotherapy, 2012. [Epub ahead of print]; PMID[22330930].
[Pubmed]. HIV_0203-021612.

5. Prediction of HIV-1 Protease/Inhibitor Affinity using Rosetta Ligand. Lemmon, G., K. Kaufmann, and J. Meiler, Chemical Biology & Drug Design, 2012. [Epub ahead of print]; PMID[22321894].
[Pubmed]. HIV_0203-021612.

6. SHAPE-directed Discovery of Potent shRNA Inhibitors of HIV-1. Low, J.T., S.A. Knoepfel, J.M. Watts, O. Ter Brake, B. Berkhout, and K.M. Weeks, Molecular Therapy, 2012. [Epub ahead of print]; PMID[22314289].
[Pubmed]. HIV_0203-021612.

7. Interaction of I50V Mutant and I50L/A71V Double Mutant HIV-Protease with Inhibitor TMC114 (Darunavir): Molecular Dynamics Simulation and Binding Free Energy Studies. Meher, B.R. and Y. Wang, The Journal of Physical Chemistry B, 2012. [Epub ahead of print]; PMID[22239286].
[Pubmed]. HIV_0203-021612.

8. Conjugation of Cell-penetrating Peptides Leads to Identification of anti-HIV Peptides from Matrix Proteins. Narumi, T., M. Komoriya, C. Hashimoto, H. Wu, W. Nomura, S. Suzuki, T. Tanaka, J. Chiba, N. Yamamoto, T. Murakami, and H. Tamamura, Bioorganic & Medicinal Chemistry, 2012. 20(4): p. 1468-1474; PMID[22277590].
[Pubmed]. HIV_0203-021612.

9. A Synthetic C34 Trimer of HIV-1 gp41 Shows Significant Increase in Inhibition Potency. Nomura, W., C. Hashimoto, A. Ohya, K. Miyauchi, E. Urano, T. Tanaka, T. Narumi, T. Nakahara, J.A. Komano, N. Yamamoto, and H. Tamamura, ChemMedChem, 2012. 7(2): p. 205-208; PMID[22247043].
[Pubmed]. HIV_0203-021612.

10. Inhibition of Human Immunodeficiency Virus Replication by Cell Membrane-crossing Oligomers. Posch, W., S. Piper, T. Lindhorst, B. Werner, A. Fletcher, H. Bock, C. Lass-Florl, H. Stoiber, and D. Wilflingseder, Molecular Medicine, 2012. 18(1): p. 111-122; PMID[22105607].
[Pubmed]. HIV_0203-021612.

11. Truncated Reverse Isoxazolidinyl Nucleosides: A New Class of Allosteric HIV-1 Reverse Transcriptase Inhibitors. Romeo, R., S.V. Giofre, B. Macchi, E. Balestrieri, A. Mastino, P. Merino, C. Carnovale, G. Romeo, and U. Chiacchio, ChemMedChem, 2012. [Epub ahead of print]; PMID[22323191].
[Pubmed]. HIV_0203-021612.

12. The Role of Natural Polymorphisms in HIV-1 CRF02_AG Protease on Protease Inhibitor Hypersusceptibility. Santos, A.F., D.M. Tebit, M.S. Lalonde, A.B. Abecasis, A. Ratcliff, R.J. Camacho, R.S. Diaz, O. Herchenroder, M.A. Soares, and E.J. Arts, Antimicrobial Agents and Chemotherapy, 2012. [Epub ahead of print]; PMID[22330918].
[Pubmed]. HIV_0203-021612.

13. Homology Model-Guided 3D-QSAR Studies of HIV-1 Integrase Inhibitors. Sharma, H., X. Cheng, and J.K. Buolamwini, Journal of Chemical Information and Modeling, 2012. [Epub ahead of print]; PMID[22256860].
[Pubmed]. HIV_0203-021612.

14. Exploiting the Anti-HIV-1 Activity of Acyclovir: the Suppression of Primary and Drug-Resistant HIV Isolates and its Potentiation by Ribavirin. Vanpouille, C., A. Lisco, A. Introini, J.C. Grivel, A. Munawwar, M. Merbah, R. Schinazi, M. Derudas, C. McGuigan, J. Balzarini, and L. Margolis, Antimicrobial Agents and Chemotherapy, 2012. [Epub ahead of print]; PMID[22314523].
[Pubmed]. HIV_0203-021612.

15. Elvitegravir : A Once-daily Inhibitor of HIV-1 Integrase. Wills, T. and V. Vega, Expert Opinion on Investigational Drugs, 2012. 21(3): p. 395-401; PMID[22321026].
[Pubmed]. HIV_0203-021612.

16. Molecular Mechanism of HIV-1 Integrase-vDNA Interactions and Strand Transfer Inhibitor Action: A Molecular Modeling Perspective. Xue, W., H. Liu, and X. Yao, Journal of Computational Chemistry, 2012. 33(5): p. 527-536; PMID[22144113].
[Pubmed]. HIV_0203-021612.

ISI Web of Knowledge citations

17. Cytotoxicity, Antioxidant, and Antimicrobial Activities of Novel 2-Quinolone Derivatives Derived from Coumarin. Al-Amiery, A.A., R.I.H. Al-Bayati, K.Y. Saour, and M.F. Radi, Research on Chemical Intermediates, 2012. 38(2): p. 559-569; ISI[000299175500023].
[WOS]. HIV_0203-021612.

18. The Structure-bioresponse Relationships Studies of Nucleoside Derivatives Conjugated with the 1-Adamantane Moiety. Bayat, Z. and A.R.R. Yassavoli, Russian Journal of Physical Chemistry A, 2012. 86(2): p. 210-214; ISI[000299088600011].
[WOS]. HIV_0203-021612.

19. A Structural Model of the HIV-1 REV-integrase Complex: The Molecular Basis of Integrase Regulation by REV. Benyamini, H., A. Loyter, and A. Friedler, Biochemical and Biophysical Research Communications, 2011. 416(3-4): p. 252-257; ISI[000298827800005].
[WOS]. HIV_0203-021612.

20. Antiviral Activities of Sulfated Polysaccharides Isolated from Sphaerococcus coronopifolius (Rhodophytha, Gigartinales) and Boergeseniella thuyoides (Rhodophyta, Ceramiales). Bouhlal, R., C. Haslin, J.C. Chermann, S. Colliec-Jouault, C. Sinquin, G. Simon, S. Cerantola, H. Riadi, and N. Bourgougnon, Marine Drugs, 2011. 9(7): p. 1187-1209; ISI[000298926700003].
[WOS]. HIV_0203-021612.

21. De Novo Design of Small Molecule Inhibitors Targeting the LEDGF/p75-HIV Integrase Interaction. Cavalluzzo, C., A. Voet, F. Christ, B.K. Singh, A. Sharma, Z. Debyser, M. De Maeyer, and E. Van der Eycken, Rsc Advances, 2012. 2(3): p. 974-984; ISI[000299177000034].
[WOS]. HIV_0203-021612.

22. Recent Advances in Developing Small Molecules Targeting RNA. Guan, L.R. and M.D. Disney, ACS Chemical Biology, 2012. 7(1): p. 73-86; ISI[000299241300009].
[WOS]. HIV_0203-021612.

23. Pharmacophore Modeling of Some Novel Indole beta-Diketo acid and Coumarin-based Derivatives as HIV Integrase Inhibitors. Jain, S.V., L.V. Sonawane, R.R. Patil, and S.B. Bari, Medicinal Chemistry Research, 2012. 21(2): p. 165-173; ISI[000298882100005].
[WOS]. HIV_0203-021612.